multimmune GmbH

..........delivering innovative cancer theranostics

NEWS

June 2018

Graham Pockley to present at the European Oncology Convention (London, 6-7 June 2018) 

May 2018

Graham Pockley to present at the 3rd Annual Advances in Immuno-oncology Congress (London, 24-25 May 2018) 

February 2018

Graham Pockley to present at the 13th Annual Biomarkers Congress (Manchester, UK; 15-16 February 2018).

September 2017

Graham Pockley presents on the theranostic potential of multimmune's platform technologies at the 4th Global Precision Medicine & Biomarker Summit (Munich, 21-22 September 2017)

May 2017

Graham Pockley presents on the theranostic potential of multimmune's platform technologies at the 2nd Annual Advances in Immuno-oncology Congress - Scientific Advisory Panel (London, 15-16 May 2017). He was also a member of the Scientific Advisory Panel)

March 2017

Graham Pockley presents on the theranostic potential of multimmune's platform technologies at the' Next Gen Immuno-Oncology Congress in London (13-14 March 2017. He was also a member of the Scientific Advisory Board Member)

May 2016

Graham Pockley presents on the theranostic potential of multimmune's platform technologies at the 'Advances in Immuno-Oncology' Congress in London (May 12-13)

November 2015

Gabriele Multhoff publishes new data on the mi-lipHsp70dx diagnostic assay: Correlation of Hsp70 serum levels with gross tumor volume and composition of lymphocyte subpopulations in patients with squamous cell and adeno non-small cell lung cancer

October 2015: Professor A. Graham Pockley, PhD appointed as CEO of multimmune GmbH. More details on Graham Pockley can be found here

September 2015: CESAR Prize 2015 awarded to Prof. Dr Gabriele Multhoff at a ceremony in Innsbruck, Austria


August 2015: SMi Group release interview with Professor A. Graham Pockley

Recruiting into a Phase II clinical trial for the treatment of non small lung cell carcinoma in 7 centres across Germany